



INVITATION

Targeted approaches to improve outcomes in AML

13:00–14:30, Sunday 26 March 2017

Hall 1, Exhibition Area, Marseille Chanot, Palais des Congrès

Redefining the ALL landscape through innovation

17:00–18:45, Sunday 26 March 2017

Salle Les Goudes 2, Marseille Chanot, Palais des Congrès




Pfizer
Oncology

This meeting is organised and funded by Pfizer © 2017 Pfizer GmbH. All rights reserved.

March 2017. PP-INO-EUR-0085





Dear Colleagues

On behalf of Pfizer Oncology, we would like to invite you to two Pfizer satellite symposia taking place during the EBMT 2017 Congress at the Marseille Chanot, Palais des Congrès in Marseille, France. At Pfizer Oncology, we are passionate about developing breakthrough innovative medicines that transform outcomes for patients with haematological malignancies.

Historically, treatment of adult acute leukaemia has been based on combination chemotherapy regimens, which offer limited survival benefit for the majority patients and are associated with significant toxicity. Improved understanding of the molecular biology of disease has led to the development of novel targeted therapies that promise to improve outcomes for patients. In our symposia, an international faculty of experts will discuss:

1. The molecular biology and treatment of acute myeloid leukaemia (AML), with a focus on the promising role of anti-CD33 therapies and the treatment of elderly patients
2. Novel antibody-directed therapies that are transforming the acute lymphoblastic leukaemia (ALL) treatment landscape

We hope the symposia will provide you with valuable opportunities to learn and share information, and we look forward to welcoming you to Marseille.



Dr Roxanne Ferdinand

Medical Director

International Developed Markets (IDM)

Pfizer Oncology

Chair's invitation: Targeted approaches to improve outcomes in AML

13:00–14:30, Sunday 26 March 2017

Hall 1, Exhibition Area, Marseille Chantot, Palais des Congrès, Marseille, France

Dear Colleagues

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium titled '**Targeted approaches to improve outcomes in AML**'.

Outcomes in AML have seen little improvement over the past 30 years, and standard chemotherapy often fails to induce durable disease remission, especially in elderly patients. Recent advances in molecular classification have heralded a new era in the treatment of AML, with novel targeted agents demonstrating improved clinical outcomes over standard therapy.

We hope that you will join us for an interactive symposium, in which experts in the field of AML will discuss recent advances in the molecular characterisation of AML and consider the promising role of anti-CD33 treatment. The expert faculty will also focus on elderly patients with AML, and discuss the innovative approaches showing promising efficacy in this poor prognosis patient group.

I look forward to welcoming you to Marseille and I hope you will join us for what promises to be an informative and engaging symposium.



Prof. Jorge Sierra (Chair)
Hospital de la Santa Creu i Sant Pau
Autonomous University of Barcelona, Spain

PROGRAMME

Chair: Prof. Jorge Sierra

13:00

Welcome and introduction

Prof. Jorge Sierra

13:05

AML: Biology, prognostic markers and therapeutic targets

Prof. Jorge Sierra

13:30

The promising role of anti-CD33 treatment in AML

Prof. Hervé Dombret

14:00

Treating elderly patients with AML: Challenges and emerging opportunities

Prof. Giovanni Martinelli

14:25

Closing remarks

Prof. Jorge Sierra

Chair's invitation: Redefining the ALL landscape through innovation

17:00–18:45, Sunday 26 March 2017

Salle Les Goudes 2, Marseille Chano, Palais des Congrès, Marseille, France

Dear Colleagues

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium titled '**Redefining the ALL landscape through innovation**'.

Clinical development in adult ALL has advanced rapidly in recent years. As a result, therapeutic options have progressed beyond standard chemotherapy, and the relapsed/refractory (R/R) ALL landscape continues to evolve as a greater number of novel targeted therapies emerge.

We hope that you will join us for an interactive symposium, in which experts in the ALL field will discuss novel antibody-directed therapy options in R/R ALL and consider the evolving role of transplantation in the R/R setting. The expert faculty will also discuss how we can best translate trial data into clinical practice in R/R ALL, with a focus on patient outcomes and the future treatment landscape.

I look forward to seeing you at what promises to be an informative and stimulating symposium.



Prof. José Ribera (Chair)

ICO-Hospital Universitari Germans Trias i Pujol

Josep Carreras Research Institute

Barcelona, Spain

PROGRAMME

Chair: Prof. José Ribera

17:00

Welcome and introduction

Prof. José Ribera

17:05

Novel antibody-directed therapy options in ALL

Prof. José Ribera

17:30

The evolving role of transplantation in R/R ALL

Prof. Marion Subklewe

17:55

Translating the trial data into clinical practice in ALL

- How can these data improve outcomes for patients with R/R ALL?
Prof. Karl-Anton Kreuzer
- How will these data change the future treatment landscape of ALL?
Prof. Alessandro Rambaldi

18:40

Closing remarks

Prof. José Ribera



Pfizer
Oncology

This meeting is organised and funded by Pfizer © 2017 Pfizer GmbH. All rights reserved.

March 2017, PP-INO-EUR-0085

